Skip to main content
. 2023 Jul 19;6(10):e202301946. doi: 10.26508/lsa.202301946

Table 1.

Antibodies used in study.

Target Company Product number Clone Lot Validation
aPKC-ι BD Biosciences 610207 41/PKCλ 7219769 siRNA KD validated by Western blotting this study and reference (71)
aPKC-ι Atlas Antibodies HPA026574 N/A 24060 Validation statement on the manufacturer’s website
aPKC-ζ Atlas Antibodies HPA021851 N/A A1138749 siRNA KD validated by Western blotting in this study and reference (20)
Total aPKC Santa Cruz Biotechnologies sc-17781 H1 C1122 Knockdown validated reference (72)
AKT(pan) Cell Signaling Technology 2920 40D4 8 None found
phospho Ser473 AKT Cell Signaling Technology 4060 D9E 25 None found; in house validated with AKT inhibitor
Gasdermin-E AbCam ab215191 EPR19859 GR3279425 Knockout validated by manufacturer
Gasdermin-E Santa Cruz Biotechnologies sc393162 G-9 K0121 None found
cleaved GSDMD Asp275 Cell Signaling Technology 36425 E7H9G 3 None found
β-actin Cell Signaling Technology 8457 D6A8 7 None found
β-actin Cell Signaling Technology 3700 8H10D 18 None found
Ezrin Invitrogen PA5-18541 N/A UH2820922 None found
Phospho Thr567 Ezrin Invitrogen PA5-37763 N/A WA3173311 None found
EEA1 R&D Systems MAB8047 871546 CIIB030041 None found
Cleaved Caspase-3 Asp175 Cell Signaling Technology 9661 N/A 47 None found
E-cadherin R&D Systems MAB18381 180215 JAT00221031 None found